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Disruption of the hippocampal
and hypothalamic blood–brain barrier
in a diet‑induced obese model of type
II diabetes: prevention and treatment
by the mitochondrial carbonic anhydrase
inhibitor, topiramate
Therese S. Salameh1,2 , William G. Mortell1, Aric F. Logsdon1,2, D. Allan Butterfield3 and William A. Banks1,2*

Abstract
Background: Type II diabetes is a vascular risk factor for cognitive impairment and increased risk of dementia.
Disruption of the blood–retinal barrier (BRB) and blood–brain barrier (BBB) are hallmarks of subsequent retinal edema
and central nervous system dysfunction. However, the mechanisms by which diet or metabolic syndrome induces
dysfunction are not understood. A proposed mechanism is an increase in reactive oxygen species (ROS) and oxidative
stress. Inhibition of mitochondrial carbonic anhydrase (mCA) decreases ROS and oxidative stress. In this study, topiramate, a mCA inhibitor, was examined for its ability to protect the BRB and BBB in diet-induced obese type II diabetic
mice.
Methods: BBB and BRB permeability were assessed using 14C-sucrose and 99mTc-albumin in CD-1 mice fed a lowfat (control) or a high-fat diet. Topiramate administration was compared to saline controls in both preventative and
efficacy arms examining BRB and BBB disruption. Body weight and blood glucose were measured weekly and body
composition was assessed using EchoMRI. Metabolic activity was measured using a comprehensive laboratory animal
monitoring system. Brain tissues collected from the mice were assessed for changes in oxidative stress and tight junction proteins.
Results: High-fat feeding caused increased entry of 14C-sucrose and 99mTc-albumin into the brains of diet-induced
obese type II diabetic mice. Increased permeability to 14C-sucrose was observed in the hypothalamus and hippocampus, and attenuated by topiramate treatment, while increased permeability to 99mTc-albumin occurred in the whole
brain and was also attenuated by topiramate. Treatment with topiramate decreased measures of oxidative stress and
increased expression of the tight junction proteins ZO-1 and claudin-12. In the retina, we observed increased entry of
99m
Tc-albumin simultaneously with increased entry into the whole brain during the preventative arm. This occurred
prior to increased entry to the retina for 14C-sucrose which occurred during the efficacy arm. Treatment with topiramate had no effect on the retina.
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Conclusions: Blood–brain barrier and blood–retinal barrier dysfunction were examined in a mouse model of
diet-induced obese type II diabetes. These studies demonstrate that there are spatial and temporal differences in
14
C-sucrose and 99mTc-albumin permeability in the brain and retina of diet-induced obese type II diabetic mice. Topiramate, a mitochondrial carbonic anhydrase inhibitor, is efficacious at both preventing and treating BBB disruption in
this diet-induced obese type II diabetic mouse model.
Keywords: Type II diabetes, Blood–brain barrier, Blood–retinal barrier, Hypothalamus, Hippocampus, Topiramate

Introduction
Type II diabetes mellitus, as well as obesity and consumption of Western diets, are known vascular risk factors for
cognitive impairment and increased risk of dementia
[1, 2]. Emerging clinical evidence and studies in animal
models of metabolic syndrome suggest that alterations in
the integrity of the cerebrovascular blood–brain barrier
(BBB) are associated with cognitive decline [3]. This phenomenon also occurs with visual impairment as observed
with disturbances in blood–retinal barrier (BRB) integrity in diabetic retinopathy. The BBB and BRB provide a
structural and functional barrier, which impedes and regulates the influx of compounds from the blood into the
brain or retina, respectively. There is growing evidence
suggesting that the disruption of the BRB and BBB is an
early hallmark of the subsequent retinal edema and central nervous system (CNS) dysfunction [4, 5]. However,
the mechanisms by which diet or metabolic syndrome
induces dysfunction of the BBB and BRB are not completely understood.
High-fat (HF) diet consumption causes BBB disruption
in a variety of animal models of obesity regardless of the
diet compositions; examples include high energy diets
and diets rich in saturated fatty acids [3, 6–8]. Type II
diabetes, designated by hyperglycemia and insulin resistance, is associated with cognitive dysfunction characterized by microvascular and neurovascular unit changes.
Changes in the brain microvasculature are characterized
by altered permeability, cerebral extravasation of plasma
molecules, neuroinflammatory and oxidative milieu, and
progressive loss of neuronal function. These features are
all associated with type II diabetes, although there are a
limited number of studies examining the effects of diabetes on BBB integrity. In a clinical study, patients with
type II diabetes showed increased BBB permeability to
gadolinium diethylenetriamine pentaacetic acid (DTPA;
570 Da) by magnetic resonance imaging [9]. In an animal study, in high-fat diet fed insulin-resistant mice, BBB
dysfunction was shown to precede cognitive decline and
neurodegeneration [10]. In KKAy mice, a model of type
II diabetes, Min et al. demonstrated that blocking angiotensin II type 1 receptors to activate peroxisome proliferator-activated receptor (PPAR)-γ protected against
cognitive decline by preserving the integrity of the BBB

[11]. More recently, Rom et al. published a paper examining BBB disruption using the fluorescent tracer, sodiumfluorescein (NaF) in the leptin receptor deficient db/
db mouse model [12]. These publications assessed BBB
integrity using either non-quantitative techniques such
as Evans Blue or IgG extravasation or non-reliable quantitative methods such as sodium fluorescein [13]. Here,
we studied disruption of the BBB and BRB in a dietinduced obese model of type II diabetes using a quantitative approach of radiolabeled ligands of varying sizes.
Although there is a great deal of diversity in microvascular and macrovascular complications associated with
type II diabetes, many arise through the same hyperglycemia-associated pathways mediated by the overproduction of superoxide [14, 15]. Increased oxidative stress is
thought to precede the onset of high-fat diet induced
insulin resistance and obesity [16]. In numerous studies,
increased oxidative stress is a major driving force leading to BBB disruption and cognitive impairment [17–24].
Disruption to the brain microvasculature arises in streptozotocin (STZ)-induced rodent models of type I diabetes
[25, 26]. Inhibition of mitochondrial carbonic anhydrase
(mCA) has been shown to decrease reactive oxygen species (ROS) and oxidative stress in STZ-induced diabetic
mouse brains [15, 27]. Topiramate (Topomax®; TPM), a
mCA inhibitor, prevents BBB disruption in mouse models of type I diabetes [15, 25]. Also, TPM has been efficacious in improving cognitive function in diabetic animal
models [28].
There are three critical characteristics of brain endothelium that establish the BBB: (i) tight junctions that
restrict paracellular diffusion of molecules; (ii) a reduction in the number of endocytic vesicles and lower rates
of transcytosis relative to peripheral vasculature, and
(iii) saturable transport of molecules between blood and
brain. Endothelial cells are connected by specific tight
junction proteins, such as claudins, occludins and Zona
occludens (ZO-1, ZO-2, and ZO-3) and exhibit specific
transport mechanisms and pinocytic vesicles. High-fat
diet consumption decreases expression of tight junction
proteins leading to reduced BBB integrity in parts of the
brain affected by the diet such as the hippocampus, but
not the parietal cortex or in the whole brain [6, 29–31].
In addition, decreased tight junction expression has been
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observed in STZ-induced diabetic mice and the leptinreceptor deficient db/db mice [12, 32].
In this study, we examined the effects of HF-feeding on
the BBB and BRB of outbred CD-1 mice. Changes in the
BBB and BRB permeability were quantitatively assessed
using two different size markers, 99mTc-labeled albumin
(65 kDa) and 14C-labeled sucrose (342 Da). We demonstrated that treatment with the mitochondrial carbonic
anhydrase inhibitor (mCAi), TPM, was able to both prevent disruption from occurring and was efficacious as
a treatment for BBB disruption in type II diabetes. We
examined oxidative stress in this model by measuring
markers of lipid peroxidation and protein oxidation and
demonstrated that TPM was able to attenuate the oxidative stress induced in this model of type II diabetes mellitus. In addition, we examined changes in tight junction
proteins and demonstrated that TPM treatment was able
to prevent the loss of claudin-12 and ZO-1 after HF-diet
consumption.

Materials and methods
Animals

Male CD-1 mice, 8 weeks of age, purchased from Charles
River Laboratories (Wilmington, MA, USA), were used
for all experiments. CD-1 mice have not been extensively utilized as a diet-induced obese model. However,
as these are outbred mice it is important to study dietinduced obesity in them. In other mouse models, females
have been found to be resistant to diet-induced obesity
and less likely to develop hyperglycemia [33, 34], and
therefore, for these studies we used male mice. Mice had
ad libitum access to food and water and were placed on a
12-h light/dark cycle. All studies were performed under
protocols in adherence with the Guide for the Care and
Use of Laboratory Animals and approved by the Institutional Animal Care and Use Committee at the Veterans
Affairs Puget Sound Health Care System (VAPSHCS).
The data presented here is in compliance with the Animal Research: Reporting in Vivo Experiments (ARRIVE)
guidelines.
Study design

Male CD-1 mice (8 weeks of age; n = 235) were split
into two arms, in the first arm, the prevention arm, mice
were placed on their respective diets and TPM administered simultaneously (Fig. 1a). The mice were divided
into 4 groups: low-fat (LF) diet + saline (n = 40), LF
diet + TPM (n = 40), high-fat (HF) diet + saline (n = 40),
HF-diet + TPM (n = 40). As this is an outbred model,
we assumed that not all mice placed on HF diet would
develop obesity and become hyperglycemic, thus a high
n at the start was necessary to achieve statistical significance at the endpoint. Mouse diets were purchased
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from Research Diets, Inc. (High fat—D12492; Low fat—
D12450J; New Brunswick, NJ, USA) and matched for
sucrose (7%). For 16 weeks, topiramate (T0575; SigmaAldrich, St. Louis, MO, USA; TPM) was administered
daily by subcutaneous injection at a dose of 5 mg/kg. This
aligns with the dosing for therapeutic use in humans.
Topiramate was dissolved in dimethylsulfoxide (DMSO)
at 1:4 (wt/vol) and further dissolved in saline. Control
mice were given an equivalent amount of DMSO in
saline. Weekly weight measurement allowed for adjustment in dosing. Non-fasted blood glucose was measured weekly using the AlphaTRAK2 blood glucometer
(Zoetis, Parsippany, New Jersey, USA) from the tail vein.
High-fat fed mice were considered type II diabetic, and
included in the analysis if their non-fasted blood glucose
was 2.5 standard deviations above the mean for the LFfed control mice. As a result, the permeability studies
examining the brain and retina had an n in each group
of: LF diet + saline (n = 10), LF diet + TPM (n = 10), HF
diet + saline (n = 11), and HF diet + TPM (n = 8). Brain
tissue and serum were collected for use in oxidative
stress analysis, protein analysis, immunohistochemical
analysis, and in the Bioplex Pro Mouse Diabetes assay.
From this tissue collection, there was an n in each group
of: LF diet + saline (n = 14), LF diet + TPM (n = 14), HF
diet + saline (n = 17), and HF diet + TPM (n = 12). After
adjustment for blood glucose, we had an n in each group
of: LF diet + saline (n = 14), LF diet + TPM (n = 14), HF
diet + saline (n = 7), and HF diet + TPM (n = 5).
In the second arm of the study, the efficacy arm
(Fig. 1a), CD-1 mice were fed LF or HF diet for 20 weeks
to develop obesity before they were started on TPM.
There were 75 mice designated for use in this arm of the
study. During the 20-week feeding period, mice were
housed four to a cage, and body weight and non-fasted
blood glucose were monitored monthly. After 20 weeks
of being fed LF or HF diet, mice were split, two to a
cage, and into four groups: LF diet + saline (n = 10), LF
diet + TPM (n = 11), HF diet + saline (n = 27), and HF
diet + TPM (n = 27). Mice were given an injection of
saline ± TPM for an additional 16 weeks with weight and
blood glucose measured weekly, while being maintained
on their respective diets. After adjustment for blood
glucose, mice used for permeability analysis totaled:
LF diet + saline (n = 5), LF diet + TPM (n = 6), HF
diet + saline (n = 10), and HF diet + TPM (n = 9). Brain
tissue and serum were also collected from the second
arm for use in oxidative stress, protein analysis, immunohistochemical analysis, and in the Bioplex Pro Mouse
Diabetes assay. From this tissue collection, there was an
n in each group of: LF diet + saline (n = 5), LF diet + TPM
(n = 5), HF diet + saline (n = 17), and HF diet + TPM
(n = 18). After adjustment for blood glucose, we had an
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Fig. 1 Effects of diet and topiramate treatment on body composition and blood glucose in CD-1 mice. A schematic diagram illustrating the
difference in design between arm 1 and 2 of the study (a). Total body weight over the 16 weeks of TPM treatment for arm 1 (b; started with HF
diet and thus prior to obesity) and arm 2 (f; started after establishment of obesity). HF consumption led to significant increases in body weight
compared to LF diet in both arms. Topiramate treatment had no effect on weight gain. Change in fat mass as a percentage calculated using fat
mass measured at the beginning and end of the treatment cycle for arm 1 (c) and arm 2 (g) of the study. Change in lean mass presented as a
percentage change from the beginning of the treatment cycle for arm 1 (d) and arm 2 (h) of the study. Topiramate had no effect on lean and fat
mass. Nonfasted measurements of blood glucose over the 16 week treatment period for arm 1 (e) and arm 2 (i). In both arms, HF feeding led to
a significant increase in nonfasted blood glucose, which was not effected by TPM treatment. Values are expressed as mean ± SD. Significance
was determined by a one-way analysis of variance followed by Newman–Keuls post-test for HF vs. LF, LF vs. LF TPM, and HF vs. HF TPM. *p < 0.05;
**p < 0.01; #p < 0.001

n in each group of: LF diet + saline (n = 5), LF diet + TPM
(n = 5), HF diet + saline (n = 15), and HF diet + TPM
(n = 12).
Three mice died during feeding/treatment (LF
diet + saline, n = 1, and HF diet + saline, n = 2) due to
unrelated causes. Sixteen mice died during anesthesia (LF
diet + saline, n = 1, LF diet + TPM, n = 4, HF diet + saline,
n = 3, and HF diet + TPM, n = 8).
Radiolabeled albumin and sucrose permeability
experiments

Mice were anesthetized with an intraperitoneal (ip) injection of 40% urethane. Once anesthetized, mice received
an injection into the jugular vein of 0.2 mL of 1% bovine
serum albumin (BSA) lactated Ringer’s solution containing 14C-sucrose (10 × 106 cpm/mouse) and 99mTc-albumin (5 × 106 cpm/mouse). To reduce exposure to ethanol
(used by manufacturer to dissolve 14C-sucrose), the ethanol was evaporated in the fume hood and the 14C-sucrose

resuspended in 1% BSA lactated Ringer’s solution. Recovery after evaporation results in 5–6 × 106 cpm/mouse of
14
C-sucrose being injected intravenously. Bovine albumin (A7030; Sigma-Aldrich, St. Louis, MO, USA) was
radioactively labeled with 99mTc using a stannous tartrate
solution acidified with HCl (20 min room temperature
incubation) then purified on a Sephadex G-10 column.
Fractions were collected and assessed using 15% trichloroacetic acid. All proteins showed greater than 90% activity in the precipitate. The injection circulated for 30 min
before the vascular space was washed out with ice-cold
lactated Ringer’s solution (20 mL in 2 min). The brain
was excised and dissected into: pons-medulla, midbrain,
cerebellum, frontal cortex, occipital cortex, parietal cortex, thalamus, hypothalamus, hippocampus, and striatum. The retina and vitreous humor were also collected,
as well as the olfactory bulbs. Serum was collected by
centrifuging blood (3200 rpm; 10 min at 4 °C) isolated
from the descending abdominal aorta.
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99m

Tc-albumin radioactivity was measured using a
gamma counter (Wizard2; PerkinElmer, Shelton, CT,
USA; 3 min counts). The samples were then processed for
measuring in the beta counter (TriCarb 3110TR; PerkinElmer; 60 min counts). Data is expressed as a ratio of
the amount of radioactivity measured in the tissue and
serum (T/S) in units of µL/g calculated by the following
equation:


T/S (g/µL) = cpm/g brain tissue /(cpm/µL serum)
Body composition

A EchoMRI 4-in-1 instrument (Echo Medical Systems,
Houston, TX, USA) used quantitative magnetic resonance (QMR) to determine lean body and fat mass of
the mice at the beginning and end of the study. Triplicate
measurements were taken using plastic restrainer tubes
with unanaesthetized mice. The procedure was performed by the Rodent Metabolic and Behavioral Phenotyping Core at the VAPSHCS.
Metabolic activity

Metabolic parameters, physical activity, and food intake
were measured in male CD-1 mice (n = 8 per group) as
previously described [35]. Animals were monitored for
72 h (12 h light/dark cycle at thermoneutrality 30 °C)
in a comprehensive laboratory animal monitoring system (CLAMS; Columbus Instruments, Columbus OH,
USA). Data was collected in 20 min intervals to measure
oxygen consumption (VO2), respiratory quotient (RQ),
energy expenditure, food intake, total physical activity,
and ambulatory activity. Mice were administered saline
or 5 mg/kg TPM at 10 a.m. daily.
Bio‑plex pro mouse diabetes assay

A collection of metabolism-related factors [ghrelin,
glucose-dependent insulinotropic peptide (GIP), glucagon-like peptide-1 (GLP-1), glucagon, insulin, leptin,
plasminogen activator inhibitor-1 (PAI-1), and resistin]
were measured in serum samples collected from LF- and
HF-fed mice treated with saline or 5 mg/kg TPM using
the murine Bioplex Pro diabetes assay kit according
to the manufacturers protocol (Bio-Rad Laboratories,
Hercules, CA, USA). We pooled data from animals in
arm 1 with arm 2 as there was no significant difference
between the groups. For example, LF arm 1 was pooled
with LF arm 2 after t-test was completed to show they
were not statistically different. After adjusting for blood
glucose levels, we obtained the following n in each group:
LF diet + saline (n = 10), LF diet + TPM (n = 11), HF
diet + saline (n = 8), and HF diet + TPM (n = 8).
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Oxidative stress measurements

To examine oxidative stress in this model, we measured
levels of protein carbonyls, 3-nitrotyrosine (3-NT) and
4-hydroxynonenal (HNE) as previously described [36].
Protein carbonyls and 3-NT are measurements of protein
oxidation and HNE is a measurement of lipid oxidation.
These measurements were determined immunochemically. Protein samples (250 ng) from the brains of CD-1
mice fed LF- and HF-diet with and without TPM treatment were blotted onto a nitrocellulose membrane with
a slot blot apparatus. In the case of protein carbonyls,
protein samples were derivatized by 2,4-dinitrophenylhydrazine (DNPH) to react with protein carbonyls to form
protein hydrazones as previously described [29]. The
membranes were incubated with rabbit polyclonal antiDNPH antibody (1:100 dilution) to measure protein carbonyls, anti-nitrotyrosine antibody (1:200 dilution) and
anti-4-hydroxynonenal polyclonal antibody (1:5000 dilution). Blots were developed using fast tablet (BCIP/NBT;
Sigma-Aldrich) and quantified using Scion Image (PC
version of Macintosh- compatible NIH image) software.
No non-specific background binding of the primary or
secondary antibodies was found.
Confocal microscopy of tight junction proteins

Dissected mouse brains were immediately post-fixed
in 4% paraformaldehyde in PBS at 4 °C and then equilibrated with cryoprotectant (30% sucrose in PBS) and
stored at 4 °C for up to 6 months until analyzed. Sagittal sections embedded in OCT (Tissue-Tek, Torrance,
CA, USA) were cut at 50 μm thickness from bisected
brains with a CM1850UV cryostat (Leica, Buffalo Grove,
IL, USA). Antigen retrieval was performed by washing the sections in PBS (3 × 5 min), transferring them
to 50 mM sodium citrate (pH 9.0) and then heating at
80 °C for 30 min. Sections cooled to room temperature
were washed (3 × 5 min) in PBS. A mouse on mouse kit
(Vector Laboratories, Burlingame, CA, USA) was used in
accordance with the manufacturer’s recommendations.
The following antibodies were applied overnight at 4 °C:
mouse monoclonal anti-occludin (Invitrogen, Carlsbad,
CA; 1:100), rabbit monoclonal anti-caveolin-1 (D46G3;
Cell Signaling, Danvers, MA; 1:1000), rat anti-ZO-1
(Clone R40.76; Millipore Sigma, Burlington, MA; 1:100),
rabbit anti-GLUT-1 (Millipore Sigma; 1:1000). Goat secondary antibodies labeled with Alexa Cy3 or Alexa F
 luor®
488 were applied for 2 h (Jackson Immunoresearch, West
Grove, PA, USA; 1:1000). Floating tissue sections were
cover slipped with a drop of Prolong® Gold Antifade
Reagent with or without DAPI (Invitrogen, Eugene, OR,
USA). Confocal microscopy was performed on the hypothalamus with a Leica TCS SP5 II microscope with Leica
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objectives (20× and 0.7 numerical aperture). All confocal
microscopic images were acquired and processed using
image adjustments limited only to linear contrast and
brightness adjustments applied identically between and
within groups.
Immunoblot analysis

Whole cell lysate extracts were prepared by lysing hemibrains in lysis buffer (25 mM Tris, pH 7.5, 0.15 M NaCl,
1 mM phenylmethylsulfonylfluoride, 1% Triton X-100
and complete protease and phosphatase inhibitor cocktails, Sigma-Aldrich, Inc.; St. Louis, MO, USA) using
a beadbeater (2 pulses for 30 s each at 4500 rpm). Cell
debris was removed by centrifugation at 14,000 rpm for
20 min at 4 °C. Amount of protein in each sample was
determined using the BCA protein assay kit (Pierce;
Rockford, IL, USA). 20 µg of protein lysate was subjected
to electrophoresis in denaturing 4–12% SDS-PAGE.
Membranes were probed for caveolin-1 (1:1000; Cell
Signaling Technology; Beverly, MA, USA), claudin-5
(1:1000; ThermoFisher Scientific; Waltham, MA, USA),
claudin-12 (1:1000; ThermoFisher Scientific; Waltham,
MA, USA) and ZO-1 (1:1000; Invitrogen; Carlsbad, CA,
USA) overnight at 4 °C. As a loading control, membranes were probed for β-actin (1:10,000). The enhanced
chemiluminescence western blot was digitalized with
a LAS4000 CCD imaging system (GE Healthcare, USA)
and analyzed by ImageQuant TL software.
Statistical analysis

Results are expressed as a mean ± standard deviation.
Statistical analysis was done on the groups using analysis of variance (ANOVA) followed by Newman–Keuls
post-test.

Results
Topiramate has no effect on body composition
and non‑fasted blood glucose levels

Male CD-1 mice (Charles River Laboratories; 8 weeks of
age) had a baseline weight of 34.21 ± 0.17 g. Mice were
placed in one of two arms: arm one, examining the role of
TPM in prevention of BBB dysfunction, started 16-week
TPM treatment or vehicle simultaneously with the
change in diet; arm two, examining the efficacy of TPM
as treatment in reversing BBB disruption, started TPM
treatment after 20 weeks of diet consumption (when BBB
disruption is known to be present), continuing mice on
the assigned diet for an additional 16 weeks.
After 4 weeks of consumption, mice fed a HF-diet
showed a significant increase in body weight compared to mice on a LF-diet (Fig. 1b). This was maintained until the study endpoint. Consistent with the
literature, TPM treatment had no effect on body weight
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and body composition in these mice (Fig. 1b–d). The
basal non-fasted blood glucose of the CD-1 mice was
178.68 ± 2.24 mg/dL. After 9 weeks on HF-diet, CD-1
mice showed a significant increase in non-fasted blood
glucose compared to LF-diet fed mice (167.2 ± 10.85 mg/
dL in LF vs. 281.9 ± 20.29 mg/dL in HF; p < 0.0001)
(Fig. 1e). There was no significant difference in non-fasted
blood glucose between saline and TPM treated mice on
either the LF- or HF-diet. CD-1 mice on LF-diet had a
baseline weight of 49.33 ± 1.31 g, while those on HF-diet
weighed 67.39 ± 1.19 g (p < 0.0001) after 20 weeks on
their respective diets. There was no significant difference
in body weight between saline and TPM treated mice on
either diet throughout the second arm (Fig. 1f ). There
was no effect on fat mass (Fig. 1g) or lean mass (Fig. 1h)
in these animals. In this arm of the study, LF-fed mice
had a basal non-fasting blood glucose of 150.9 ± 2.6 mg/
dL, while those on the HF-diet had a significantly higher
basal non-fasting blood glucose of 250.05 ± 9.35 mg/dL
(p < 0.05). Topiramate treatment had no effect on blood
glucose levels (Fig. 1i).
Topiramate has no effect on metabolic activity
and metabolism‑related hormones

Low- and high-fat fed CD-1 mice were placed into metabolic chambers after treatment with TPM for 1 week
or 16 weeks in both arm 1 and arm 2 (Fig. 2). Topiramate treatment had no effect on oxygen use (Fig. 2a),
food intake (Fig. 2c), or activity (Fig. 2e, f ). An RQ of
0.7 indicates preferential utilization of lipids, whereas
a value of 1.0 indicates use of carbohydrates. Topiramate treatment did not affect the RQ of animals on
the respective diets (Fig. 2d). In arm 2, HF-diet consumption resulted in a significant increase (p < 0.0001)
in energy expenditure compared to LF-fed controls
(Fig. 2b). This increase was significantly attenuated
with TPM treatment. Analysis of serum metabolites
showed that HF-feeding led to a significant decrease
in ghrelin levels (Fig. 3a) and a significant increase in
GIP (Fig. 3b), insulin (Fig. 3e) and leptin (Fig. 3f ). HFfeeding caused no significant change in the level of
GLP-1, glucagon, PAI-1, and resistin compared to the
LF-treated group. Treatment with TPM had no significant effect on any of the metabolites measured compared to their LF and HF-treated counterparts (Fig. 3).
High‑fat diet consumption results in BBB permeability
to 99mTc‑albumin which is attenuated by topiramate
treatment

Blood–brain barrier dysfunction was measured using
99m
Tc-albumin (65 kDa). Results indicate that at 16 weeks
in arm 1, the whole brain shows increased permeability to

Salameh et al. Fluids Barriers CNS

(2019) 16:1

Page 7 of 17

Fig. 2 Metabolic activity of topiramate-treated CD-1 mice. Metabolic data collected from the laboratory animal monitoring system (CLAMS) after
1 week and 16 weeks of TPM administration as a preventative (arm 1) or efficacy (arm 2) agent from LF diet + saline (n = 8), LF diet + TPM (n = 8), HF
diet + saline (n = 8), and HF diet + TPM (n = 8) in each arm. Mice were administered treatments once daily and measured for 72 h. Data collected
includes a oxygen consumption ( VO2; mL/h/kg), b energy expenditure (kcal/h), c food intake (FI; grams/h), d respiratory quotient (RQ: VCO2/
VO2), e total activity (beam breaks/h), and f ambulatory activity (sequential beam breaks/h). Values are expressed as mean ± SD. Significance was
determined by a one-way analysis of variance followed by Newman–Keuls post-test between HF vs. LF, LF vs. LF TPM, and HF vs. HF TPM. *p < 0.05;
#
p < 0.001

Salameh et al. Fluids Barriers CNS

(2019) 16:1

Page 8 of 17

Fig. 3 Effect of diet and topiramate on metabolism-related hormones. Serum samples collected from LF diet + saline (n = 10), LF diet + TPM
(n = 11), HF diet + saline (n = 8), and HF diet + TPM (n = 8). Serum was measured for a ghrelin, b glucose-dependent insulinotropic peptide, GIP, c
glucagon-like peptide-1, GLP-1, d glucagon, e insulin, f leptin, g plasminogen activator inhibitor-1, PAI-1, and h resistin. Ghrelin showed a significant
decrease after HF-feeding, while GIP, insulin, and leptin showed a significant increase. Topiramate treatment had no significant effect at either
low- or high-fat feeding. Values are expressed as mean ± SD. Significance was determined by a one-way analysis of variance followed by Newman–
Keuls post-test between HF vs. LF, LF vs. LF TPM, and HF vs. HF TPM. *p < 0.05; **p < 0.01; #p < 0.001
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Fig. 4 Measurement of blood–brain barrier permeability changes in diet-induced obesity. These histograms are representative of data highlighted
in Tables 1 and 2. 14C-labeled sucrose (342 Da; Table 2) was used to measure BBB permeability changes in the whole brain (a prevention; g efficacy),
hypothalamus (b prevention; h efficacy), and hippocampus (c prevention; i efficacy). 99mTc-labeled albumin (65 kDa; Table 1) was used to measure
BBB permeability changes in the whole brain (d prevention; j efficacy), hypothalamus (e prevention; k efficacy), and hippocampus (f prevention; l
efficacy). Values are expressed as mean ± SD. Significance was determined by a one-way analysis of variance followed by Newman–Keuls post-test
for HF vs. LF, LF vs. LF TPM, and HF vs. HF TPM. *p < 0.05; **p < 0.01; #p < 0.001

99m

Tc-albumin in the HF-fed animals (1.102 ± 0.495 µL/g
in LF vs. 3.174 ± 2.237 µL/g in HF; p < 0.01) (Fig. 4d;
Table 1). This observation was made at the whole brain
level, and specifically in the hypothalamus (Fig. 4e;
p < 0.05) and cerebellum (p < 0.05), with other regions

trending towards significance (frontal cortex, parietal
cortex, occipital cortex, and pons-medulla; p < 0.10).
Topiramate treatment was able to attenuate BBB disruption in the whole brain (3.17 ± 0.79 µL/g in HF vs.
0.667 ± 0.413 µL/g in HF TPM; p < 0.01) (Fig. 4e; Table 1).
Similar findings were observed in the whole brain after
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Table 1 Blood–brain barrier and blood–retinal barrier disruption to 99mTc-albumin
Region

Whole brain
Retina
Vitreous humor
Olfactory bulb
Striatum
Frontal cortex
Hypothalamus
Hippocampus
Thalamus
Parietal cortex
Occipital cortex
Cerebellum
Midbrain
Pons-medulla
99m

Prevention

Efficacy

LF

LF TPM

HF

1.102 ± 0.495

1.599 ± 1.160

3.174 ± 2.237a
a

3.941 ± 1.141

3.591 ± 1.513

6.062 ± 1.613a

18.20 ± 7.654
2.110 ± 1.677

1.892 ± 0.995

21.37 ± 8.186
1.701 ± 0.789

1.746 ± 1.905

HF TPM

38.46 ± 20.53

2.267 ± 1.871

1.840 ± 1.167

0.861 ± 0.815

1.081 ± 0.799

2.079 ± 1.736

0.630 ± 0.538

2.759 ± 2.324

3.603 ± 3.855

1.528 ± 0.411
1.196 ± 0.640

1.119 ± 0.665

1.314 ± 0.841
0.738 ± 0.430

0.947 ± 0.825

1.472 ± 0.654

2.506 ± 2.400
1.951 ± 1.424

1.615 ± 1.486

1.982 ± 1.370
1.087 ± 1.029

1.908 ± 0.943

2.191 ± 1.267

16.41 ± 13.15a
3.094 ± 3.046

2.576 ± 2.362

2.817 ± 2.521

a

2.851 ± 2.483

2.994 ± 2.301

3.057 ± 1.969

Tc-albumin was used to assess permeability after TPM treatment

LF

LF TPM

HF

0.667 ± 0.413b
a

0.883 ± 0.452

0.927 ± 0.473

1.672 ± 0.719a

6.277 ± 2.636a

5.398 ± 2.516

8.791 ± 4.617

7.917 ± 5.659

29.98 ± 21.77

2.696 ± 1.483

1.976 ± 1.669

19.27 ± 7.943

1.697 ± 0.392

0.795 ± 0.770

31.13 ± 8.985

1.326 ± 0.653

0.681 ± 0.512

HF TPM
a

36.40 ± 11.65

2.383 ± 1.321

0.823 ± 0.776

0.534 ± 0.096b
29.62 ± 8.061

6.694 ± 3.447

1.486 ± 0.547

0.412 ± 0.273

0.949 ± 0.589

0.752 ± 0.344

0.773 ± 0.356

1.241 ± 0.765

0.522 ± 0.090b

0.984 ± 0.765

0.598 ± 0.458

1.094 ± 0.723

1.742 ± 1.112a

0.339 ± 0.273b

1.359 ± 1.050

0.371 ± 0.125b

3.123 ± 2.274b
1.273 ± 1.366

0.871 ± 0.802

0.655 ± 0.406

0.990 ± 1.150

1.936 ± 2.206

2.548 ± 1.490

0.815 ± 1.025

0.594 ± 0.510

0.723 ± 0.412

1.070 ± 0.530

1.072 ± 0.742

0.515 ± 0.288

1.361 ± 0.670

0.659 ± 0.667

0.710 ± 0.316

0.745 ± 0.411

0.669 ± 0.547

0.899 ± 0.470

0.799 ± 0.482

1.176 ± 0.420

0.223 ± 0.397

1.328 ± 1.258
1.103 ± 0.720

0.908 ± 0.458

1.260 ± 0.791

1.671 ± 0.800

0.579 ± 0.436

0.367 ± 0.219

0.406 ± 0.233b

0.752 ± 0.495

0.289 ± 0.220b
1.598 ± 2.272

Units, µL/g. Values are expressed as mean ± SD. Significance was determined by a one-way analysis of variance followed by Newman–Keuls post-test

LF low-fat diet + saline group, LF TPM low-fat diet + topiramate group, HF high-fat diet + saline group, HF TPM high-fat diet + topiramate group
a

Significance in comparison to LF control

b

Significance in comparison to HF

36 weeks of HF-feeding (0.883 ± 0.452 µL/g in LF vs.
1.672 ± 0.719 µL/g in HF; p < 0.05, Fig. 4j; Table 1). At this
time point, the hippocampus showed significant increased
permeability (Fig. 4f; p < 0.05), with other regions trending towards significance (frontal cortex, parietal cortex, occipital cortex, thalamus, and midbrain; p < 0.10).
Topiramate treatment also attenuated BBB permeability at 36 weeks in arm 2 (1.672 ± 0.719 µL/g in HF vs.
0.534 ± 0.096 µL/g in HF TPM; p < 0.001, Fig. 4j; Table 1).
HF-feeding also led to increased permeability to 99mTcalbumin in the retina at 16 weeks (18.20 ± 7.654 µL/g in
LF vs. 38.46 ± 20.53 µL/g in HF; p < 0.05) and 36 weeks
(19.27 ± 7.943 µL/g in LF vs. 36.40 ± 11.65 µL/g in HF;
p < 0.05, Table 1). Topiramate did not attenuate the effects
of HF-feeding in the retina and vitreous humor.
High‑fat diet consumption results in hypothalamic
and hippocampal increased permeability to 14C‑sucrose
which is attenuated by topiramate treatment

Blood–brain barrier permeability was measured using
14
C-sucrose (342 Da). In Table 2, we show data collected to examine the ability of TPM to prevent BBB
disruption in the brain. Results indicate that at 16 weeks
of arm 1 (prevention), the brain shows increased

permeability to 14C-sucrose in the hypothalamus
(21.42 ± 6.130 µL/g in LF vs. 50.96 ± 27.71 µL/g in HF;
p < 0.05; Fig. 4b) and hippocampus (7.753 ± 1.220 µL/g
in LF vs. 11.73 ± 3.021 µL/g in HF; p < 0.05; Fig. 4c)
(Table 2). Topiramate treatment was able to attenuate the
increased permeability to 14C-sucrose in the hypothalamus (50.96 ± 27.71 µL/g in HF vs. 23.12 ± 4.293 µL/g
in HF TPM; p < 0.05, Table 2). Also shown in Table 2
is data collected to determine the efficacy (arm 2) of
TPM as a treatment for BBB disruption. Similar to
our findings in prevention (arm 1), at 36 weeks the
brain showed increased permeability to 14C-sucrose
in the hypothalamus (10.51 ± 2.365 µL/g in LF vs.
16.85 ± 3.627 µL/g in HF; p < 0.05; Fig. 4h) and hippocampus (6.070 ± 1.327 µL/g in LF vs. 8.580 ± 1.862 µL/g
in HF; p < 0.05; Fig. 4i, Table 2). Topiramate treatment
was able to attenuate BBB disruption to 14C-sucrose
in the hippocampus (8.580 ± 1.862 µL/g in HF vs.
6.594 ± 0.875 µL/g in HF TPM; p < 0.05, Table 2). At
36 weeks, the retina (138.1 ± 27.51 µL/g in LF vs.
184.1 ± 25.68 µL/g in HF; p < 0.05, Table 2) also showed
increased permeability to 14C-sucrose which was not
attenuated with TPM treatment.
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Table 2 Blood–brain barrier and blood–retinal barrier disruption to 14C-sucrose
Region

Prevention
LF

Whole brain
Retina
Vitreous humor
Olfactory bulb
Striatum
Frontal cortex
Hypothalamus
Hippocampus
Thalamus
Parietal cortex
Occipital cortex
Cerebellum
Midbrain
Pons-medulla
14

9.704 ± 2.586

Efficacy
LF TPM
12.86 ± 2.869

HF

HF TPM

10.67 ± 3.386

LF

11.59 ± 1.884

7.936 ± 3.422

LF TPM
7.568 ± 1.839

HF

HF TPM

9.584 ± 3.593

7.978 ± 2.508

161.2 ± 38.52

153.4 ± 52.74

161.3 ± 30.87

197.2 ± 42.03

138.1 ± 27.51

166.2 ± 20.10

184.1 ± 25.68a

184.1 ± 31.34a

18.58 ± 6.127

26.77 ± 14.24

23.47 ± 11.87

25.26 ± 13.44

15.74 ± 2.848

17.04 ± 4.781

17.38 ± 4.052

16.57 ± 2.744

55.53 ± 18.10

9.636 ± 2.148

9.605 ± 3.311

21.42 ± 6.130

7.753 ± 1.220
10.05 ± 2.202

8.412 ± 2.212

9.764 ± 2.013

8.223 ± 2.127

8.889 ± 3.054

11.95 ± 4.057

51.12 ± 15.29

9.643 ± 1.677

11.22 ± 3.896

24.46 ± 6.736

9.704 ± 0.950
10.41 ± 2.625

10.78 ± 3.310

12.10 ± 3.037

10.12 ± 2.517

13.09 ± 5.116

13.90 ± 3.024

48.40 ± 13.74

11.16 ± 3.700

9.428 ± 4.862

50.96 ± 27.71a
a

11.73 ± 3.021
8.770 ± 3.176

9.458 ± 3.105

10.31 ± 2.756

9.427 ± 3.065

10.51 ± 3.445

11.78 ± 4.316

C-sucrose was used to assess permeability after TPM treatment

65.70 ± 16.15

11.58 ± 2.340

11.09 ± 2.339

23.12 ± 4.293b
a

12.06 ± 2.466

10.54 ± 2.138

10.79 ± 2.743

10.53 ± 2.759

10.20 ± 1.709

12.87 ± 2.407

14.71 ± 3.700

40.69 ± 1.939

7.375 ± 2.047

5.973 ± 1.285

10.50 ± 2.365

6.070 ± 1.327

7.135 ± 0.815

6.235 ± 1.416

7.815 ± 1.858

6.832 ± 1.551

7.309 ± 1.458

9.642 ± 1.321

59.70 ± 17.77

6.979 ± 1.390

6.161 ± 0.789

12.04 ± 2.413

7.029 ± 1.186

7.107 ± 1.435

6.235 ± 1.369

6.898 ± 1.683

6.890 ± 1.142

7.321 ± 1.706

10.92 ± 2.397

55.29 ± 14.97

6.956 ± 1.072

6.422 ± 1.225

16.85 ± 3.627a

a

8.580 ± 1.862

6.421 ± 0.632

6.413 ± 1.840

7.451 ± 1.669

8.018 ± 3.389

7.913 ± 1.991

11.92 ± 6.198

60.10 ± 15.10

7.978 ± 2.517

6.029 ± 0.578

15.51 ± 2.898a

6.594 ± 0.875b
6.402 ± 0.674

5.763 ± 0.827

7.581 ± 1.401

6.654 ± 1.005

6.774 ± 1.046

10.24 ± 2.984

Units, µL/g. Values are expressed as mean ± SD. Significance was determined by a one-way analysis of variance followed by Newman–Keuls post-test

LF low-fat diet + saline group, LF TPM low-fat diet + topiramate group, HF high-fat diet + saline group, HF TPM high-fat diet + topiramate group

a

Significance in comparison to LF control

b

Significance in comparison to HF

Fig. 5 Effect of diet and topiramate on oxidative stress. Changes in 4- hydroxynonenal (HNE, a), 3-nitrotyrosine (3-NT, b), and protein carbonyls (c)
levels in mouse brain homogenates from LF- and HF-fed CD-1 mice treated with or without TPM. HF diet led to a significant increase in HNE and
3-NT compared to LF controls. These increases were attenuated with TPM treatment. HF diet had no effect on protein carbonyls. The image in d is
representative of the slot blot data used to collect these values. Values are expressed as arbitrary units, mean ± SD. Significance was determined by
a one-way analysis of variance followed by Newman–Keuls post-test for HF vs. LF, LF vs. LF TPM, and HF vs. HF TPM. *p < 0.05; **p < 0.01
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Topiramate treatment decreases oxidative stress levels
in high‑fat diet fed mice

Oxidative stress was examined in hemibrain samples
from CD-1 mice fed LF- and HF-diets and treated with
TPM. Lipid peroxidation, one measure of oxidative stress,
was assessed by measuring protein-bound 4-hydroxynonenal (HNE), a stable byproduct of lipid peroxidation.
Elevated levels of protein-bound HNE are indicative of
oxidative stress. Hyperglycemic HF-fed CD-1 mice had
significantly increased (p < 0.01) levels of protein-bound
HNE (Fig. 5a). Topiramate treatment partially prevented
the increase in oxidative stress caused by HF diet consumption since HF-fed mice treated with TPM were not
significantly different from the LF controls. Elevated levels of 3-NT, a marker of protein oxidation formed by peroxynitrite, which in turn is formed from reaction of nitric
oxide with superoxide radical anions, is another measurement of oxidative stress. Hyperglycemic HF-fed CD-1
mice had significantly increased (p < 0.01) levels of 3-NT
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compared to LF controls (Fig. 5b). HF-fed TPM treated
mice had significantly decreased (p < 0.05) levels of 3-NT
compared to their HF-fed controls. There was no significant change in protein carbonyls, another measure of
protein oxidation (Fig. 5c).
Topiramate affects the tight junction proteins, claudin‑12
and ZO‑1

Immunohistochemical techniques were used to examine the tight junction proteins ZO-1 and occludin in
the hypothalamus of CD-1 mice fed LF- or HF- diet
treated with saline or TPM. HF-fed mice showed a
significant decrease in ZO-1 (Fig. 6a) and occludin
(Fig. 6b) fluorescent intensity in the hypothalamus
(p < 0.05). Topiramate treatment partially prevented the
decrease in ZO-1 expression caused by HF diet consumption since HF-fed mice treated with TPM were
not significantly different from the LF controls. Whole
brain lysate was used to measure protein expression of

Fig. 6 Effect of diet and topiramate on tight junction protein expression using immunofluorescence. Immunohistochemical techniques were
used on tissue from the hypothalamus to examine ZO-1 (a) and occludin (b) expression in LF- and HF-fed CD-1 mice treated with or without TPM
(a). ZO-1 and occludin expression were significantly decreased with HF-diet feeding compared to LF-fed controls. TPM treatment attenuated ZO-1
expression. GLUT1 was used as a vessel marker for ZO-1 and CAV1 as a vessel marker for occludin. The merged image localizes the tight junction
staining to the vessels. Scale bar is 50 microns. Values are expressed as mean ± SD. Significance was determined by a one-way analysis of variance
followed by Newman–Keuls post-test between HF vs. LF, LF vs. LF TPM, and HF vs. HF TPM. *p < 0.05
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Fig. 7 Effect of diet and topiramate on tight junction protein expression using immunoblot. Whole brain lysate was used to examine expression of
the tight junction proteins, claudin-5, claudin-12, and ZO-1, and caveolin-1, the major structural protein of caveolae (a). HF-diet consumption led
to a significant decrease in claudin-12 and ZO-1 expression which was attenuated with TPM treatment for claudin-12 (b). There were no significant
changes in calveolin-1 or claudin-5. Values are expressed as mean ± SD and relative to the β-actin loading control. Significance was determined by a
one-way analysis of variance followed by Newman–Keuls post-test between HF vs. LF, LF vs. LF TPM, and HF vs. HF TPM. *p < 0.05; #p < 0.001

the tight junction proteins claudin-5, claudin-12, and
ZO-1, relative to β-actin expression (Fig. 7). HF-diet fed
mice showed a significant decrease in the tight junction proteins, claudin-12 (p < 0.05) and ZO-1 (p < 0.05,
Fig. 7b). Topiramate treatment attenuated the effect of
HF-diet feeding on the protein expression of claudin-12
(p < 0.05, Fig. 7b). HF-diet consumption had no significant effect on protein expression of claudin-5. In addition, we measured protein expression of caveolin-1, as
it is the major structural protein of caveolae, the membrane microdomains involved in various aspects of
vesicular trafficking [37, 38]. No change in caveolin-1
expression was observed.

Discussion
Type II diabetes is associated with cognitive dysfunction resulting in microvascular and neurovascular
unit changes. Type II diabetes is also associated with
increased ROS and oxidative stress. Topiramate, a mCAi,
has been shown to decrease ROS and oxidative stress in
an STZ-induced mouse model of type I diabetes and to
reverse cognitive impairment [15, 27, 28]. This approach
has been effective in preventing BBB disruption in STZinduced diabetes by preserving pericyte function [25,
27, 39, 40]. Here, we examined BBB and BRB disruption
in a diet-induced obese model of type II diabetes. Two
paradigms were used; in arm 1 (prevention), mice were
treated with the mCAi TPM for 16 weeks concurrently
with the onset of their LF or HF diets; in arm 2 (efficacy),
the mice were fed their LF or HF diets for 20 weeks and

then started on the 16 week TPM regimen while continuing their respective diets. As arm 1 examined the effects
of TPM prior to the onset of BBB disruptions, this had a
preventative aspect to it, whereas arm 2 examined effects
of TPM after a time when BBB lesions are established
and so had an efficacy aspect to it. Therefore, this experimental design was used to determine if TPM is effective
both in the prevention of BBB disruption and as a potential treatment.
A potential confounder to this study would have been
if TPM treatment had resulted in the reversal of diabetes. To examine this, we monitored the effect of TPM on
body weight as it has been shown, when used in combination with other drugs, to reduce adiposity in humans
and rodents and is currently being used as part of an antiobesity medication regimen [41–43]. We demonstrated
that TPM injections had no effect on body weight. This
was similar to what we observed in studies of STZinduced type I diabetes [25]. The mechanism by which
TPM induces weight loss has yet to be elucidated. Potential mechanisms include decreasing food intake, reducing body fat gain, and increasing energy expenditure [42,
43]. We did not observe changes in body weight which
could potentially be attributed to the relatively low dose
of TPM (5 mg/kg vs. 10–100 mg/kg), the route of administration (subcutaneous injections vs. oral gavage), or that
TPM was used as a single agent.
Topiramate has the potential to be an insulin sensitizing agent. This is apparent in rat models [44–46]. There is
conflicting evidence of this in mouse models and human
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studies [25, 46–49]. Topiramate treatment had no effect
on non-fasted blood glucose in our model, however, that
does not imply it did not affect insulin sensitivity. Analysis of the diabetes panel to determine if the TPM treatment had an effect on metabolic hormones revealed that
HF feeding caused an increase in GIP, leptin, and insulin
levels and a decrease in ghrelin; consistent with the literature [50–53]. However, TPM treatment did not alter
ghrelin, leptin, insulin, GIP, GLP-1, PAI-1, or resistin levels. Thus, the protective effects of TPM are not mediated
by changes to the metabolic state of the animal. This is
consistent with TPM protection being facilitated through
its ability to inhibit mitochondrial carbonic anhydrase
[15, 25].
Blood–brain barrier permeability was assessed using
two radiolabeled ligands of varying sizes, 99mTc-albumin (65 kDa) and 14C-sucrose (342 Da). The hypothalamus and hippocampus showed increased permeability
to 14C-sucrose with HF-feeding. To date, no studies
have examined permeability to a ligand this small in
an in vivo type II diabetic model using radioactive
techniques. Assessment was also completed using
99m
Tc-albumin (65 kDa). We observed increases in
99m
Tc-albumin in the whole brain after 16 weeks of HFfeeding. Increased permeability to 99mTc-albumin was
observed in the hypothalamus (at 16 weeks) and hippocampus (at 36 weeks). This was consistent with the
literature which has used other large ligands, such as
IgG (150 kDa) to examine BBB disruption [6–8]. Studies of obese animal models have shown disruption in
the hypothalamus and hippocampus, similar to our
findings in type II diabetes, which leads us to conclude
that hormone levels may potentially drive BBB disruption more so than hyperglycemia. Transcytosis is a
transcellular, vesicular based, molecular weight-independent form of capillary leakage, whereas paracellular
transport is the intercellular, tight junction proteindependent form of capillary leakage. There is no definitive method in which to distinguish the mechanism by
which 99mTc-albumin or 14C-sucrose crossed into each
brain region, since both are capable of entering through
paracellular and transcytotic routes. However, our
studies have provided evidence that 99mTc-albumin and
14
C-sucrose cross into the brain of the diabetic mouse
in distinct patterns from one another, implying that
they are using different mechanisms of entry that are
disrupted differentially.
Blood–retinal barrier disruption was also examined
in this model. Diabetic retinopathy is a major complication associated with this disease and the major cause
of blindness in Western countries. Here, we observed
increased entry of 99mTc-albumin into the retina simultaneously with increased entry into the whole brain at
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16 weeks. This occurred prior to increased entry to the
retina for 14C-sucrose which occurred at 36 weeks. That
is increased permeability to 14C-sucrose in the retina
was not found in arm one (16 weeks of HF diet), but was
found in arm 2 (36 weeks of HF diet). Pericyte loss is a
major hallmark of diabetic retinopathy, as well as in the
brain microvasculature, and in other complications of
type II diabetes [15, 54–57]. Topiramate treatment has
proven efficacious in preventing pericyte loss in the brain
of STZ-induced diabetic mice, but not in the retina [15,
25, 27]. This suggests that the mechanism of disruption
in the BRB is distinct to that of the BBB. Also, that the
mechanism of pericyte loss in the two tissue types may
be independent of one another. The actions of the mCAi
in lowering ROS may not be the appropriate target to
preventing pericyte loss in the retina.
High-fat diet consumption is associated with increased
oxidative stress. Oxidative stress affects BBB integrity
[17–19]. Studies have shown that brain levels of HNE
and 3-NT, markers of lipid peroxidation and protein
oxidation, respectively, are increased in brain tissue,
and other tissues, including adipose and liver after HFdiet consumption [58–63]. Protein carbonyls have been
shown to be increased in the brain with specific types of
HF-diets which include lard [64] and TPM treatment has
been shown to reduce these markers of oxidative stress
in STZ-induced diabetic mice [15, 28]. Topiramate treatment of the hyperglycemic type II diabetic mice in this
study demonstrated that it was efficacious in reducing
oxidative stress in this model. Decreasing oxidative stress
is a mechanism by which TPM acts to improve BBB
integrity and TPM has been shown to act on pericytes
to decrease reactive oxygen species and improve cellular
respiration in the presence of high glucose [39, 40].
In regions of the brain where BBB integrity has been
disrupted, such as the hippocampus, studies have shown
that tight junction protein expression is decreased [29,
30]. However, when regions not affected by HF diet consumption are examined, such as the parietal cortex, or at
the whole brain level, the effect on tight junction expression is often absent [6, 31]. In this study, we had access
to hemibrains of mice shown to have BBB disruption, for
the preparation of lysate to examine the effect of HF-diet
consumption and TPM treatment on tight junction protein expression. We demonstrated that HF-diet led to a
decreased expression of ZO-1, claudin-12 and occludin,
which was attenuated or partially attenuated with TPM
treatment. Examining tight junction protein expression
in specific regions where BBB disruption has occurred
may implicate other tight junction proteins in this model.
This provides a second mechanism by which HF-diet
consumption leads to a decline in BBB integrity and TPM
is able to attenuate the effect.
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Obesity has been associated with disorders affecting the
CNS including depression and cognitive impairment. Cognitive dysfunction has been linked to the consumption of
a Western diet, a diet that contains both high levels of fat
(35–60% total kcal) and added sugars. While much of the
research done on obesity has focused on its effect in the
hypothalamus, it is now understood that obesity also affects
other brain regions including the hippocampus [65]. The
hippocampus, a brain region associated with the control
of certain learning and memory processes, is particularly
vulnerable to Western diet consumption. This study has
demonstrated that the disruption of the hypothalamus and
hippocampus are evident in animal models of type II diabetes as well as with obesity. The findings of this study demonstrate that the pattern of BBB disruption in type II diabetes
is different to that observed in type I diabetes [25]. Type I
diabetic animal models showed disruption to 14C-sucrose
(342 Da) in the cortices, thalamus, and midbrain [25, 26],
while in our diet-induced obese type II diabetic model we
showed disruption in the hypothalamus and hippocampus.
This supports findings that cognitive impairment between
type I and type II diabetics differ from one another [66, 67].
Cognitive dysfunction in type I diabetes is characterized by
a slowing of mental speed and diminished mental flexibility,
while learning and memory are spared, while in type II diabetes, learning and memory are the primary issues of cognitive impairment. Unfortunately, in a recent study, Espeland
et al. demonstrated that long-term intensive lifestyle intervention, using diet and exercise, in type II diabetics had no
effect on cognitive function, despite improvements in health
[68]. This supports our belief that hormone levels play a
stronger role in determining BBB disruption and subsequent cognitive impairment.

Conclusion
Blood–brain barrier and blood–retinal barrier dysfunction were examined in a mouse model of diet-induced
obese type II diabetes. Mitochondrial carbonic anhydrase
inhibition, using the drug topiramate, was used as potential prevention and treatment strategy in this model.
Increased permeability to 14C-sucrose was detected in
the hypothalamus and hippocampus, and increased permeability to 99mTc-albumin in the whole brain. In the
retina, increased entry of 99mTc-albumin was detected
at 16 weeks while increased entry to 14C-sucrose was
not detected until 36 weeks. Our studies indicate that
topiramate is efficacious at both preventing and treating BBB disruption in the brain, but not retina, in this
diet-induced obese type II diabetic mouse model. These
studies demonstrate that there are spatial and temporal
differences in 14C-sucrose and 99mTc-albumin permeability in the brain and retina of diet-induced obese type II
diabetic mice.
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